Merit Medical Stock Falls Despite Positive WRAPSODY Trial Results

Zacks09-19

Merit Medical Systems, IncMMSI announced favorable 6-month results from the randomized arteriovenous (AV) fistula arm of its pivotal WRAPSODY Arteriovenous Access Efficacy (WAVE) trial. The data were ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468537633?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0y7pHAbd2ah0Qunql6MeVQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b35c1538fbd501bfb8e20b349661fde7","is_english":true,"pubTime":"2024-09-19 00:24","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2468537633","market":"us","top_or_hot":-1,"title":"Merit Medical Stock Falls Despite Positive WRAPSODY Trial Results","media":"Zacks","content":"<div>\n<p>Merit Medical Systems, IncMMSI announced favorable 6-month results from the randomized arteriovenous (AV) fistula arm of its pivotal WRAPSODY Arteriovenous Access Efficacy (WAVE) trial. The data were ...</p>\n\n<a href=\"https://finance.yahoo.com/news/merit-medical-stock-falls-despite-162400461.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merit Medical Stock Falls Despite Positive WRAPSODY Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerit Medical Stock Falls Despite Positive WRAPSODY Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-19 00:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/merit-medical-stock-falls-despite-162400461.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Merit Medical Systems, IncMMSI announced favorable 6-month results from the randomized arteriovenous (AV) fistula arm of its pivotal WRAPSODY Arteriovenous Access Efficacy (WAVE) trial. The data were ...</p>\n\n<a href=\"https://finance.yahoo.com/news/merit-medical-stock-falls-despite-162400461.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATIP","symbol_name":"ATI Physical Therapy Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/merit-medical-stock-falls-despite-162400461.html","article_id":"2468537633","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0y7pHAbd2ah0Qunql6MeVQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b35c1538fbd501bfb8e20b349661fde7"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468537633","pubTimestamp":1726676640,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Merit Medical Systems, IncMMSI announced favorable 6-month results from the randomized arteriovenous  fistula arm of its pivotal WRAPSODY Arteriovenous Access Efficacy  trial. The data were presented at the Cardiovascular and Interventional Radiological Society of Europe.The WAVE trial is evaluating WRAPSODY, a cell-impermeable endoprosthesis, in dialysis patients for maintaining vessel patency. Data from the AV fistula arm expands upon the previously completed first-in-human study, WRAPSODY FIRST, and will support the company’s Premarket Approval application to the FDA. WRAPSODY is already approved and available for use in Europe and Brazil.Following the news, shares of MMSI declined 1.1% to $98.51 at yesterday’s close. The company's ongoing advancements and positive product developments are expected to counterbalance the challenges it faces, like integrating acquisitions, managing manufacturing transitions and dealing with currency fluctuations.Impact of WRAPSODY WAVE Trial Results o","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATIP":"ATI Physical Therapy Inc.","UHS":"Universal Health Services Inc Cl","MMSI":"Merit Medical Systems","BK4133":"新能源发电业者","BK4585":"ETF&股票定投概念","WAVE":"Eco Wave Power Global AB (publ)","BK4185":"保健护理机构","BK4588":"碎股","BK4539":"次新股","LU0566484027.USD":"安本美国小盘成长股","AVAH":"Aveanna Healthcare Holdings Inc.","BK4198":"医疗保健用品","BK4196":"保健护理服务","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H"},"translate_title":"尽管WRAPSODY试验结果积极，但Merit Medical股价仍下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATIP":1,"AVAH":1,"MMSI":1,"WAVE":1,"UHS":0.9},"content_text":"Merit Medical Systems, IncMMSI announced favorable 6-month results from the randomized arteriovenous (AV) fistula arm of its pivotal WRAPSODY Arteriovenous Access Efficacy (WAVE) trial. The data were presented at the Cardiovascular and Interventional Radiological Society of Europe.\nThe WAVE trial is evaluating WRAPSODY, a cell-impermeable endoprosthesis, in dialysis patients for maintaining vessel patency. Data from the AV fistula arm expands upon the previously completed first-in-human study, WRAPSODY FIRST, and will support the company’s Premarket Approval application to the FDA. WRAPSODY is already approved and available for use in Europe and Brazil.\nFollowing the news, shares of MMSI declined 1.1% to $98.51 at yesterday’s close. The company's ongoing advancements and positive product developments are expected to counterbalance the challenges it faces, like integrating acquisitions, managing manufacturing transitions and dealing with currency fluctuations.\nIts accelerated introduction of cutting-edge products, combined with strong patient and physician adoption as well as ongoing regulatory approvals, is expected to drive growth.\nImpact of WRAPSODY WAVE Trial Results on Merit Medical\nData from the AV fistula arm of the WAVE trial demonstrated that patients treated with ERAPSODY achieved a 27% higher target lesion primary patency rate of 89.8% compared to 62.8% for those receiving percutaneous transluminal angioplasty. The rate of adverse events was similar between the two groups. The data shows that WRAPSODY improves the maintenance of sufficient blood flow through the AV fistula in dialysis patients compared to PTA.\nWRAPSODY's superior efficacy highlights its importance in extending the longevity of vascular access in dialysis treatment, which is critical for patient survival. These positive results mark a pivotal step toward improving vascular access maintenance for dialysis patients, positioning WRAPSODY as a potential new standard of care. The six-month efficacy data is highly compelling, allowing clinicians to assess WRAPSODY's ability to extend vascular access for patients. WRAPSODY has the potential to become the new standard of care.\nIn the United States, WRAPSODY is currently being used under an Investigational Device Exemption from the FDA.\nMarket Prospects Favoring MMSI\nPer a report in Future Market Insights, the global arteriovenous fistula (AVF)treatment market size was worth $765.8 million in 2023. It is anticipated to reach $1.4 billion by 2033 at a CAGR of 5.9%.\nThe robust growth is likely to be driven by the introduction of innovative methods like photodynamic therapy, antiangiogenic therapy and sclerotherapy. However, effective and easy-to-use treatments are still in development, driving ongoing innovation and shaping market trends. Nonetheless, the high prevalence of AVF and limited treatment options continue to fuel market expansion.\nMMSI Stock Price Performance\nShares of Merit Medical have risen 29.7% year to date compared with the industry’s 0.8% growth. The S&P 500 has witnessed an 18.1% rise in the same time frame.\nImage Source: Zacks Investment Research\nZacks Rank & Key Picks\nCurrently, Merit Medical carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space are Universal Health Services UHS, ATI Physical Therapy ATIP and Aveanna Healthcare AVAH. While Universal Health Services sports a Zacks Rank #1 (Strong Buy), ATI Physical Therapy and Aveanna Healthcare carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nUniversal Health Services has an estimated long-term growth rate of 19%. UHS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.\nUniversal Health Services has gained 41.1% compared with the industry's 34.8% growth year to date.\nATI Physical Therapy's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.25%.\nATIP's shares have surged 5.5% year to date compared with the industry’s 18.6% growth.\nAveanna Healthcare's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 47.5%.\nAVAH's shares have surged 104.5% year to date compared with the industry’s 15.7% growth.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nUniversal Health Services, Inc. (UHS) : Free Stock Analysis Report\nMerit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report\nAveanna Healthcare Holdings Inc. (AVAH) : Free Stock Analysis Report\nATI Physical Therapy, Inc. (ATIP) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468537633"}